Charissa Wijnands (Nijmegen / NL), Peter Karel (Nijmegen / NL), Jolein Gloerich (Nijmegen / NL), Vincent Bonifay (Lisses / FR), Luciano Di Stefano (Lisses / FR), Theo Luider (Rotterdam / NL), Martijn Vanduijn (Rotterdam / NL), Sandra Croockewit (Nijmegen / NL), Elizabeth de Kort (Nijmegen / NL), Daan Castelijn (Amsterdam / NL), Claudia Stege (Amsterdam / NL), Alain van Gool (Nijmegen / NL), Niels van de Donk (Amsterdam / NL), Joannes Jacobs (Nijmegen / NL)
Introduction
Multiple Myeloma (MM) is a common blood cancer caused by malignant plasma cells that overproduce a monoclonal immunoglobulin (M-protein). The M-protein is a personalized biomarker. Since current M-protein quantification methods lack in sensitivity, we have developed a LC-MS/MS method to quantify clonotypic peptides from the variable region of the M-protein (MS-MRD). Therapeutic monoclonal antibodies (t-MAbs) play an important role in MM treatment but often lead to a depletion of total immunoglobulin (Ig) levels which requires intravenous IgG administration. Monitoring t-MAb and polyclonal Ig levels could provide important information for therapy administration. Here, we demonstrate the monitoring of M-proteins, t-MAbs, and Ig constant regions in one LC-MS/MS run providing a holistic view of therapy response kinetics.
Methods
Clonotypic peptides for M-proteins and t-MAbs were selected based on linearity and sensitivity in serial dilutions. Ig constant regions of all classes and subclasses were monitored using (sub)class-unique peptides. With a multi-enzyme de novo protein sequencing approach, we obtained the M-protein sequences (M-inSight, Sebia). Patient sera collected between 2013 and 2024 from four MM patients who have received multiple treatment lines were analyzed with MS-MRD. Sera were analyzed using PASEF DDA on a timsTOF pro - PaSER platform (Bruker). Subsequently, patient-specific libraries and dia-PASEF methods were generated for sensitive disease and therapy monitoring. Peak areas of the selected clonotypic, t-MAb, and Ig constant region peptides were filtered from raw dia-PASEF data files and further processed for quantification.
Results
Clonotypic peptides were identified in all four patients and serial dilutions demonstrated an assay sensitivity of 1 mg/L, which is 1,000-fold more sensitive compared to routine M-protein evaluation. MS-MRD analyses in patient 1 and 2 showed the lowest M-protein concentrations since diagnosis in 2013 and 2016 with teclistamab (a novel anti-CD3 and -BCMA bispecific antibody) given under compassionate use as the 8th and 6th line of therapy respectively. Monitoring all administered t-mAbs was feasible in all patients and the measured concentrations corresponded to the administration dates. A 1,000-fold lower concentration of teclistamab compared to daratumumab and isatuximab (anti-CD38 t-MAbs) was observed, corresponding to the significantly different dosing of these drugs. MS-MRD revealed rapid and deep depletion of all Ig classes which is a side-effect of teclistamab, followed by a selective increase in IgG due to intravenous IgG administration to counter this side-effect.
Conclusion
This case series demonstrated the robustness of the M-protein as personalized biomarker during follow-up periods of up to 11 years. Quantification of the M-protein, t-mAbs, and all Ig (sub)classes within a single mass spectrometry run enables dynamic monitoring of novel therapeutics and therapy response.
Auf unserem Internetauftritt verwenden wir Cookies. Bei Cookies handelt es sich um kleine (Text-)Dateien, die auf Ihrem Endgerät (z.B. Smartphone, Notebook, Tablet, PC) angelegt und gespeichert werden. Einige dieser Cookies sind technisch notwendig um die Webseite zu betreiben, andere Cookies dienen dazu die Funktionalität der Webseite zu erweitern oder zu Marketingzwecken. Abgesehen von den technisch notwendigen Cookies, steht es Ihnen frei Cookies beim Besuch unserer Webseite zuzulassen oder nicht.